Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
Cybin ($CYBN) completed the acquisition of a Phase I DMT study from Entheon Biomedical. The study is expected to accelerate the clinical development path of CYB004, Cybin's proprietary deuterated DMT molecule used as a potential treatment for anxiety disorders. Press Release
Optimi Health (OPTI | $OPTHF) finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre, a mental health service provider, including psychedelic-assisted therapies. Optimi will supply Bloom with natural psilocybin to begin conducting their previously announced clinical trial. Press Release
Filament Health ($FH | $FLHLF) has been issued a third describing essential technology for transforming psychedelic raw materials into pharmaceutical-grade, standardized drug candidates and closed their private placement, raising C$2.5M. Details
PharmaTher Holdings ($PHRM | $PHRRF) has been provided a Notice of Allowance for patent application which includes claims intended to cover ketamine as a potential treatment of Parkinson’s Disease and motor disorders.Press Release
Awakn Life Sciences ($AWKN | $AWKNF) provided operational updates. Highlights included the initiation of their Innovative Licensing and Access Pathway application for their lead program Project Kestrel, filed a Patent Cooperation Treaty for MDMA-assisted therapy for the treatment of AUD and signed a Letter of Intent with Mindcure. Press Release
Nova Mentis Life Science ($NOVA | $NMLSF) presented at the International Fragile X Conference, highlighting recent research results showing significantly modulated behavioural and cognitive defects from a very low microdose formulation of the Company's proprietary psilocybin drug (NM-1001). Press Release
Wall Street Journal: Investors See Far Out Profits in Psychedelic Medicine
Washington Post: Ann Shulgin, Pioneer Of Psychedelics In Therapy
New York Times: Taking the Magic Out of Psychedelics
Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.